MA31062B1 - Agents tensioactifs reconstitues presentant des proprietes ameliorees. - Google Patents

Agents tensioactifs reconstitues presentant des proprietes ameliorees.

Info

Publication number
MA31062B1
MA31062B1 MA31854A MA31854A MA31062B1 MA 31062 B1 MA31062 B1 MA 31062B1 MA 31854 A MA31854 A MA 31854A MA 31854 A MA31854 A MA 31854A MA 31062 B1 MA31062 B1 MA 31062B1
Authority
MA
Morocco
Prior art keywords
improved properties
reconstituted surfactants
reconstituted
relates
surfactants
Prior art date
Application number
MA31854A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Jan Johansson
Tore Curstedt
Bengt Robertson
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39079026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA31062B1 publication Critical patent/MA31062B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
MA31854A 2006-10-13 2009-05-08 Agents tensioactifs reconstitues presentant des proprietes ameliorees. MA31062B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021521 2006-10-13
PCT/IB2007/002841 WO2008044109A1 (en) 2006-10-13 2007-09-28 Reconstituted surfactants having improved properties

Publications (1)

Publication Number Publication Date
MA31062B1 true MA31062B1 (fr) 2010-01-04

Family

ID=39079026

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31854A MA31062B1 (fr) 2006-10-13 2009-05-08 Agents tensioactifs reconstitues presentant des proprietes ameliorees.

Country Status (35)

Country Link
US (2) US8183210B2 (enExample)
EP (1) EP2078038B1 (enExample)
JP (2) JP5405307B2 (enExample)
KR (1) KR101328851B1 (enExample)
CN (2) CN103169947B (enExample)
AR (2) AR063263A1 (enExample)
AU (1) AU2007306075B2 (enExample)
BR (1) BRPI0715317B1 (enExample)
CA (1) CA2666344C (enExample)
CL (1) CL2007002931A1 (enExample)
CO (1) CO6400235A2 (enExample)
CY (1) CY1114716T1 (enExample)
DK (1) DK2078038T3 (enExample)
EA (1) EA015802B1 (enExample)
ES (1) ES2438727T3 (enExample)
GE (1) GEP20125531B (enExample)
HR (1) HRP20140052T1 (enExample)
IL (1) IL198075A (enExample)
JO (1) JO2963B1 (enExample)
MA (1) MA31062B1 (enExample)
ME (2) ME02326B (enExample)
MX (1) MX343064B (enExample)
MY (1) MY148127A (enExample)
NO (1) NO342038B1 (enExample)
NZ (1) NZ576189A (enExample)
PE (1) PE20081184A1 (enExample)
PL (1) PL2078038T3 (enExample)
PT (1) PT2078038E (enExample)
RS (1) RS53172B (enExample)
SI (1) SI2078038T1 (enExample)
TN (1) TN2009000099A1 (enExample)
TW (1) TWI388333B (enExample)
UA (1) UA94477C2 (enExample)
WO (1) WO2008044109A1 (enExample)
ZA (1) ZA200902481B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011559A2 (en) 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
CN101948526B (zh) * 2010-09-02 2012-12-05 华东理工大学 一种肺泡表面活性蛋白质(sp-b和sp-c)的分离纯化方法
US9815869B2 (en) 2012-02-09 2017-11-14 University Of Rochester SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
US20130303726A1 (en) * 2012-04-17 2013-11-14 Chiesi Farmaceutici S.P.A. Method for the preparation of surfactant peptides
BR112015009486B1 (pt) 2012-11-21 2022-06-14 Chiesi Farmaceutici S.P.A Surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
EP3393489B1 (en) * 2015-12-17 2021-09-01 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Synthetic lung surfactant with enhanced stability and effectiveness
CA3016810C (en) 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for administering ppar.gamma. agonists, surfactant peptides and phospholipids
CN109562139A (zh) 2016-08-24 2019-04-02 奇斯药制品公司 包含重构肺表面活性物质组合物的稳定药物制剂
US20230257446A1 (en) 2020-01-28 2023-08-17 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
EP4228691A4 (en) * 2020-10-16 2025-01-01 Biosuperior Technology, Inc. PULMONARY TREATMENT COMPOSITIONS
WO2025024609A1 (en) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides for lung surfactant compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US7065342B1 (en) * 1999-11-23 2006-06-20 Gofigure, L.L.C. System and mobile cellular telephone device for playing recorded music
ITMI20021058A1 (it) 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
WO2008011559A2 (en) * 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
EP2022798A1 (en) 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides

Also Published As

Publication number Publication date
WO2008044109A1 (en) 2008-04-17
HK1134497A1 (en) 2010-04-30
PT2078038E (pt) 2013-12-12
JO2963B1 (en) 2016-03-15
EA200900373A1 (ru) 2009-10-30
US20130079275A1 (en) 2013-03-28
ES2438727T3 (es) 2014-01-20
TW200824705A (en) 2008-06-16
ME02326B (me) 2016-06-20
US8183210B2 (en) 2012-05-22
CN103169947B (zh) 2014-10-29
CO6400235A2 (es) 2012-03-15
CY1114716T1 (el) 2016-10-05
CA2666344A1 (en) 2008-04-17
IL198075A0 (en) 2011-08-01
CN103169947A (zh) 2013-06-26
TN2009000099A1 (en) 2010-08-19
NZ576189A (en) 2011-09-30
JP5405307B2 (ja) 2014-02-05
CN101522711A (zh) 2009-09-02
AU2007306075A1 (en) 2008-04-17
AR063263A1 (es) 2009-01-14
PL2078038T3 (pl) 2014-05-30
KR20090083892A (ko) 2009-08-04
HRP20140052T1 (hr) 2014-02-28
MEP12109A (en) 2011-12-20
US9238058B2 (en) 2016-01-19
JP2013241449A (ja) 2013-12-05
AR113422A2 (es) 2020-04-29
EP2078038A1 (en) 2009-07-15
BRPI0715317A2 (pt) 2013-07-09
ZA200902481B (en) 2010-07-28
CA2666344C (en) 2017-04-18
CN101522711B (zh) 2013-11-13
EA015802B1 (ru) 2011-12-30
MY148127A (en) 2013-02-28
EP2078038B1 (en) 2013-11-20
JP2010505937A (ja) 2010-02-25
AU2007306075B2 (en) 2012-08-09
GEP20125531B (en) 2012-05-25
HK1185274A1 (en) 2014-02-14
TWI388333B (zh) 2013-03-11
SI2078038T1 (sl) 2014-02-28
RS53172B (sr) 2014-06-30
BRPI0715317B1 (pt) 2021-10-05
MX2009003638A (es) 2009-04-22
CL2007002931A1 (es) 2008-03-24
MX343064B (es) 2016-10-24
KR101328851B1 (ko) 2013-11-14
PE20081184A1 (es) 2008-09-26
NO20091441L (no) 2009-06-23
UA94477C2 (ru) 2011-05-10
US20100004173A1 (en) 2010-01-07
DK2078038T3 (da) 2013-12-02
IL198075A (en) 2016-04-21
NO342038B1 (no) 2018-03-19

Similar Documents

Publication Publication Date Title
MA31062B1 (fr) Agents tensioactifs reconstitues presentant des proprietes ameliorees.
ES2846789T3 (es) Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MA33374B1 (fr) Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
EA200401467A1 (ru) Пептиды, полученные из казеина, и их применение в терапии
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE431141T1 (de) Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
US6818621B2 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
Patel et al. Toll‐like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
AU2017252344A1 (en) Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents
US20240041987A1 (en) Novel bioactive peptide combinations and uses thereof
TW201204384A (en) Lactoferrin sequences, compositions and methods of wound treatment
CA3201966A1 (en) Pre-treatment of msc with pparb/.delta. agonist for treatment of ischemia-reperfusion injury
PT1317273E (pt) Utilizacao de quimera il-6r/il-6 na doenca de huntington
KR101169850B1 (ko) 트로락스를 포함하는 골 대사성 질환 또는 골 전이성 암 질환 예방 및 치료용 약제학적 조성물
WO2002098454A3 (en) Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
Samy et al. Wound Healing Activity and Mechanisms of Action of an Antibacterial
IL175019A0 (en) Cxcl8 antagonists, their preparation and use
TN2010000460A1 (fr) Nouveaux anticorps utiles pour le traitement du cancer